An anonymous donor’s transformational contribution will support impactful innovation and startups that result from the work of university faculty, staff and students.Continue reading
Author Archive: AZBio
Reglagene Receives FDA Orphan Drug Designation for Innovative Brain Cancer Treatment
New therapy crosses blood-brain barrier to give new hope to patients with rare, aggressive cancerContinue reading
Reglagene, Inc. Announces closing of $5.4 Million Private Placement
Company developing breakthrough therapies for brain diseases has closed oversubscribed private placement to fund clinical trial planning and R & D.
Inability to penetrate the blood-brain barrier has been a roadblock to treat brain diseases. Reglagene has addressed this and paves the way in therapies offering brain cancer patients new hope.” — Richard Austin, Ph.D., MBAContinue reading
Xcellerant Ventures Invests in Series A Funding Round for Lenoss Medical
SCOTTSDALE, Ariz.–(BUSINESS WIRE)–Xcellerant Ventures welcomes Lenoss Medical into our Venture Fund I portfolio. Lenoss Medical is disrupting the treatment of spinal fractures with their OsteoPearl VBA System. This minimally invasive and cement-free technology delivers a fully biologic solution to stabilize spinal fractures and utilizes the natural healing properties of healthy bone.Continue reading
University of Arizona selects design, build firms for CAMI
The University of Arizona Health Sciences announced December 12 it had selected McCarthy + SmithGroup to lead the design and construction of the Center for Advanced Molecular and Immunological Therapies, or CAMI, facility in downtown Phoenix.Continue reading
In Comments to FDA, AdvaMed Maintains Support of Agency’s Authority to Regulate LDTs
WASHINGTON, D.C. – Today, AdvaMedDx submitted comments in response to the Food and Drug Administration’s Proposed Rule: Medical Devices; Laboratory Developed Tests. AdvaMedDx is a division of AdvaMed representing companies that develop in vitro diagnostic (IVD) tests.
Avery Therapeutics, Inc. shares publication in Nature Communications Biology: “Biologically derived epicardial patch induces macrophage mediated pathophysiologic repair in chronically infarcted swine hearts”
TUCSON, ARIZONA, DECEMBER 11, 2023 – Avery Therapeutics, Inc., a privately held, pre-clinical stage therapeutics company, developing therapeutics for diseases of aging, inflammation and fibrosis announces a publication in Nature Communications Biology, dated November 24, 2023. The article, titled “Biologically derived epicardial patch induces macrophage mediated pathophysiologic repair in chronically infarcted swine hearts,” demonstrates a novel approach in the treatment of chronic heart failure (CHF).Continue reading
AdvaMed Announces Formation of Medical Imaging Division
World’s largest medical imaging companies join world’s largest medtech association
Continue reading
MCCCD Welcomes New Leadership to Drive Innovation and Growth
The Maricopa County Community College District (MCCCD) is pleased to announce the selection of three new executive leaders; Lee Ann Bohn, Chief Operating Officer; Dr. Heather Carter, Senior Vice Chancellor of External Affairs; and Dr. Lisa Armour, Executive Vice Chancellor and Provost. The three well-respected leaders will enhance the System’s already robust administrative talent.Continue reading